Growth Metrics

Prelude Therapeutics (PRLD) Cash from Investing Activities (2024 - 2026)

Prelude Therapeutics' Cash from Investing Activities history spans 3 years, with the latest figure at $8.5 million for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 86.33% to $8.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$228000.0, a 100.19% decrease, with the full-year FY2025 number at $53.5 million, down 40.73% from a year prior.
  • Cash from Investing Activities hit $8.5 million in Q1 2026 for Prelude Therapeutics, up from -$60.3 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for PRLD hit a ceiling of $62.2 million in Q1 2025 and a floor of -$60.3 million in Q4 2025.
  • Historically, Cash from Investing Activities has averaged $16.9 million across 3 years, with a median of $22.1 million in 2024.
  • The widest YoY moves for Cash from Investing Activities: up 273.53% in 2025, down 372.8% in 2025.
  • Tracing PRLD's Cash from Investing Activities over 3 years: stood at $22.1 million in 2024, then tumbled by 372.8% to -$60.3 million in 2025, then skyrocketed by 114.09% to $8.5 million in 2026.
  • Business Quant data shows Cash from Investing Activities for PRLD at $8.5 million in Q1 2026, -$60.3 million in Q4 2025, and $40.1 million in Q3 2025.